ASX Announcement

March 2026 Quarterly Activity Report & Appendix 4C

- **Developed a new blood-based molecular test that evaluates the cardioprotective effects of RC220 in patients in the cardioprotection and anticancer synergy (CPACS) Phase 1 trial**
- **Selected to present on (E,E)-bisantrene ability to silence MYC gene expression at the 2026 American Association of Cancer Research Annual Meeting**
- **First patient recruited to the Phase 1 HARNESS-1 clinical trial in non-small cell lung cancer patients with activating epidermal growth factor receptor mutations**
- **Strong cash balance of $19.38m at 31 March 2026**

30 April 2026

Racura Oncology Limited ("Racura") is pleased to release its Q3 FY2026 report for the period ending 31 March 2026. Racura's cash and cash equivalents totalled $19.38 million at the end of the quarter, with more than 81% of spending ($2.44m) directed toward R&D and drug manufacturing activities. Early conversion of options provided an additional $1.44m of funding, which together with continued prudent cash management, places Racura in an excellent position to fund all committed activities through CY2027.

Significant progress was made in the quarter. In January, Racura established a collaboration with Emory University (USA) to study (E,E)-bisantrene in osimertinib-resistant epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) models. In February, Racura announced the development of a new blood-based molecular test to evaluate the cardioprotective effects of RC220 in the cardioprotection and anticancer synergy (CPACS) Phase 1 trial. In March, governance approval was received, and the first patient was recruited to the HARNESS-1 lung cancer trial, along with treating the first patient in Hong Kong in the CPACS Phase 1 trial.

Late in the quarter, Racura held its first Research & Development (R&D) Symposium. Racura staff from the preclinical and clinical teams, together with external key opinion leaders, presented the scientific rationale and strategy behind Racura's clinical programs and commercial roadmap.

Management commentary

Chief Executive Officer and Managing Director Dr. Daniel Tillett commented: *"This quarter has built on the significant scientific and clinical progress made by the company over the past 12 months. We began the*

quarter by announcing our collaboration with Emory University and concluded with the enrolment of the first patient into the HARNESS-1 lung cancer trial.

The highlight of the quarter was the inaugural Racura R&D Symposium held on 24 March. I wish to thank the entire Racura team, along with the key opinion leaders who presented, for their effort in making this event a success."

Key events of the quarter

- On 14 January 2026, Racura announced it had commenced a collaboration with Emory University (Atlanta, GA, USA) to study (E,E)-bisantrene in osimertinib-resistant epidermal growth factor receptor mutated (EGFRm) non-small cell lung cancer (NSCLC). This collaborative program is led by Prof. Shi-Yong Sun, a recognised world leader in osimertinib-resistant lung cancer biology and provides Racura access to Emory's unique osimertinib-resistant cell and mouse non-small cell lung cancer (NSCLC) models and expertise. The program supports the HARNESS-1 clinical trial of RC220 aimed at delaying or preventing resistance to osimertinib arising in EGFRm NSCLC patients.
- On 11 February 2026, Racura announced the development of a new blood-based molecular test that evaluates the cardioprotective effects of RC220 in patients by quantifying its impact on molecular pathways linked to anthracycline cardiotoxicity. This test, enabled by new findings on (E,E)-bisantrene's mechanism of action (ASX Announcement: 2 October 2025), aims to provide early cardioprotective data from doxorubicin-treated patients during the RC220 dose escalation phase of the RAC-010 trial (ASX Announcement: 1 May 2025). The trial changes required to support this test are expected to enhance patient safety and improve recruitment.
- On 16 March 2026, Racura announced it had received governance approval from Monash Health for its Phase 1 clinical trial assessing the safety, tolerability and pharmacokinetics (PK) of RC220 (E,E-bisantrene) in combination with osimertinib (Tagrisso®; AstraZeneca), in patients with EGFRm NSCLC. Human ethics approval for this trial was received in November 2025 (ASX Announcement: 26 November 2025).
- On 18 March 2026, Racura announced that the company was selected to present a scientific poster at the American Association of Cancer Research (AACR) Annual Meeting 2026, held in San Diego (USA) from the 17 to 22 April 2026.
- On 19 March 2026, Racura announced the dosing of the third patient with RC220 in the CPACS Phase 1 clinical trial in advanced solid tumours and the first patient treated in Hong Kong. The patient was treated by Principal Investigator Dr Roland Ching-Yu Leung and his team at the Queen Mary Hospital. No phlebitis (vein inflammation) or other adverse events were reported following dosing of RC220.
- On 31 March 2026, Racura announced that the first patient had been recruited to its Phase 1 HARNESS-1 clinical trial. The HARNESS-1 trial aims to assess the safety, tolerability and

pharmacokinetics (PK) of RC220 (E,E-bisantrene) in combination with the standard of care tyrosine kinase inhibitor (TKI) osimertinib (Tagrisso®; AstraZeneca) in patients with EGFRm NSCLC. The first participant was consented into the trial by Principal Investigator Associate Professor Surein Arulananda and his team at Monash Health (Clayton, Victoria).

Other news from the quarter

- On 24 March 2026, Racura held its inaugural R&D Symposium at the Museum of Sydney. Presentations from the Racura preclinical and clinical teams provided a detailed overview of the science behind (E,E)-bisantrene and RC220, as well as the commercial and scientific rationale of Racura's three clinical programs in solid tumours, lung cancer and acute myeloid leukemia. In addition, presentations from external key opinion leaders provided important context and background.
- In the quarter, Racura welcomed four new members to the clinical and preclinical teams. In the clinical team, Ms Corli Merry joined as Senior Clinical & Quality Manager and Dr Anupa Kudva as Medical Director. In the preclinical team, Dr David Bourke joined as Senior CMC Manager and Ms Chelsea Penney as Research Associate II. All have made significant contributions in their short time at Racura.

Post quarter news

- On 22 April 2026, Racura announced that Dr Sumit Sahni had presented a poster entitled *"(E,E)-bisantrene silences c-MYC expression by stabilizing its promoter region G-quadruplex"* at the prestigious American Association of Cancer Research Annual Meeting held in San Diego, 17-22 April 2026. The presentation disclosed results from a range of preclinical studies demonstrating (E,E)-bisantrene silences MYC gene expression by stabilising a G-quadruplex DNA structure located in the promoter region of the c-MYC oncogene.

Summary of cash flow and quarterly activity

As of 31 March 2026, Racura held cash and equivalents of $19.38 million.

Listing rule 4.7C.3

Payments during the quarter to Related Parties amounted to $129k, comprising payments of salaries and superannuation to Executive Directors of $88k and board fees to Non-Executive Directors of $41k.

Shareholders by holding range

Racura is pleased to report that in the quarter the total number of shareholders with greater than 5000 shares had increased over the previous quarter.

Holding Ranges	Holders	Total Units	% Issued Capital
above 0 up to and including 1,000	4,312	1,731,314	0.95%
above 1,000 up to and including 5,000	2,714	6,748,361	3.71%
above 5,000 up to and including 10,000	811	6,079,370	3.34%
above 10,000 up to and including 100,000	1,578	49,760,193	27.35%
above 100,000	301	117,650,833	64.65%
Total	**9,716**	**181,970,071**	**100.00%**

Top 20 holders as of 31 March 2026

Racura is pleased to share the current Top 20 shareholders as of 31 March 2026. Shareholders can expect regular updates in future quarterly reports.

Position	Holder	Holding	% IC
1	DR DANIEL TILLETT	18,531,388	10.18%
2	MR PHILLIP RICHARD PERRY	6,403,328	3.52%
3	MR MARK PHILLIP JUAN	6,107,376	3.36%
4	DR BORJE SVEN ANDERSSON	3,925,440	2.16%
5	THE TRUST COMPANY (AUSTRALIA) LIMITED <MOF A/C>	3,708,000	2.04%
6	BNP PARIBAS NOMINEES PTY LTD <IB AU NOMS RETAILCLIENT>	2,261,751	1.24%
7	KUDOSS INVESTMENTS PTY LTD <AITKEN GLOBAL FAMILY A/C>	2,119,450	1.16%
8	MR PHILLIP RICHARD PERRY & MRS TETYANA PERRY <DONESKA SUPER FUND A/C>	1,830,000	1.01%
9	MR SANDOR HELBY	1,818,000	1.00%
10	MS MARINELLA MESSINA	1,757,377	0.97%
11	MR KIMBERLEY ROSS GARTRELL & MRS JENNIFER MARGARET GARTRELL <K&J GARTRELL SUPER FUND A/C>	1,575,000	0.87%
12	MR ALAN GILES SAURAN	1,333,888	0.73%
13	SURPION PTY LTD <M W SUHR & CO A/C>	1,250,000	0.69%
14	CITICORP NOMINEES PTY LIMITED	1,200,969	0.66%
15	MR ANTHONY JAMES ROBINSON <THE PEEKO FAMILY NO 86 A/C>	1,104,656	0.61%
16	MR BRIAN JAMES WALKER	1,064,095	0.58%
17	MR BEAU THOMAS ROBINSON <BEAU ROBINSON INVSTMNT A/C>	986,720	0.54%
18	MR VAN QUY DO	863,003	0.47%
19	3RD MAN RISK CONSULTING PTY LIMITED	760,250	0.42%
20	MR ROSS EARL HENRY	755,478	0.42%
	Total	**59,356,169**	**32.62%**
	Total issued capital	**181,970,071**	**100.00%**

-ENDS-

About Racura Oncology

Racura Oncology (ASX: RAC) is a Phase 3 clinical-stage biopharmaceutical company with a mission to silence cancer.

Racura's lead asset, (E,E)-bisantrene, is a small molecule anticancer agent that primarily functions via G4-DNA & RNA binding, leading to potent silencing of the important cancer growth regulator MYC. (E,E)-bisantrene has demonstrated therapeutic activity in cancer patients with a well-characterised safety profile. Recent discoveries made by Racura have enabled composition of matter IP filings that, upon grant, provide for up to 20 years of patent protection over (E,E)-bisantrene.

Racura is advancing a proprietary formulation of (E,E)-bisantrene (RC220) to address the high unmet needs of patients across multiple oncology indications, with a Phase 3 clinical program in acute myeloid leukaemia (AML), a Phase 1a/b program in mutant epidermal growth factor receptor non-small cell lung cancer (EGFRm NSCLC), and a Phase 1a/b program in combination with the anthracycline doxorubicin, where we aim to deliver both cardioprotection and enhanced anticancer activity for patients with solid tumours.

Racura has collaborated with Astex, Emory University, Purdue University, MD Anderson, Sheba City of Health, UNC School of Medicine, University of Wollongong, and University of Newcastle. Racura is actively exploring partnerships, licence agreements, or a commercial merger and acquisition to accelerate access to RC220 for patients with cancer across the world. Learn more at www.racuraoncology.com.

If you have any questions on this announcement, or any past Racura Oncology announcements, please visit our Interactive Announcements page.

Racura encourages all investors to go paperless by registering their details with the Company's share registry, Automic Registry Services, at www.automicgroup.com.au.

Release authorised by

Daniel Tillett, CEO

info@racuraoncology.com

Media Contact

Cherie Hartley +61 418 737 020

Cherie.hartley@irdepartment.com.au

RACURA ONCOLOGY LIMITED (RAC)

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity	
RACURA ONCOLOGY LIMITED (RAC)	
ABN	**Quarter ended ("current quarter")**
61 149 318 749	31 Mar 2026

Consolidated statement of cash flows		**Current quarter $A'000**	**Year to date (9 months) $A'000**
1.	**Cash flows from operating activities**		
1.1	Receipts from customers	-	-
1.2	Payments for		
	(a) research and development	(1,909)	(5,326)
	(b) product manufacturing and operating costs	(528)	(752)
	(c) advertising and marketing	(116)	(386)
	(d) leased assets	-	-
	(e) staff costs	(240)	(829)
	(f) administration and corporate costs	(405)	(1,157)
1.3	Dividends received (see note 3)	-	-
1.4	Interest received	200	439
1.5	Interest and other costs of finance paid	-	-
1.6	Income taxes paid	-	-
1.7	Government grants and tax incentives	-	2,780
1.8	Other (provide details if material)	(7)	31
1.9	**Net cash from / (used in) operating activities**	**(3,005)**	**(5,200)**

2.	**Cash flows from investing activities**		
2.1	Payments to acquire or for:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments	-	-

Consolidated statement of cash flows		Current quarter $A'000	Year to date (9 months) $A'000
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.2	Proceeds from disposal of:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	1
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	-	-
2.6	**Net cash from / (used in) investing activities**	**-**	**1**

3.	**Cash flows from financing activities**		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	-	3,223
3.2	Proceeds from issue of convertible debt securities	-	-
3.3	Proceeds from exercise of options	1,438	7,682
3.4	Transaction costs related to issues of equity securities or convertible debt securities	-	-
3.5	Proceeds from borrowings	-	-
3.6	Repayment of borrowings	-	-
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other (share buy-back)	-	-
3.10	**Net cash from / (used in) financing activities**	**1,438**	**10,905**

4.	**Net increase / (decrease) in cash and cash equivalents for the period**		
4.1	Cash and cash equivalents at beginning of period	20,942	13,666
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(3,005)	(5,200)

Consolidated statement of cash flows		**Current quarter $A'000**	**Year to date (9 months) $A'000**
4.3	Net cash from / (used in) investing activities (item 2.6 above)	-	1
4.4	Net cash from / (used in) financing activities (item 3.10 above)	1,438	10,905
4.5	Effect of movement in exchange rates on cash held	-	3
4.6	**Cash and cash equivalents at end of period**	**19,375**	**19,375**

5.	**Reconciliation of cash and cash equivalents** at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	**Current quarter $A'000**	**Previous quarter $A'000**
5.1	Bank balances	1,875	2,442
5.2	Call deposits	17,500	18,500
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
5.5	**Cash and cash equivalents at end of quarter (should equal item 4.6 above)**	**19,375**	**20,942**

6.	**Payments to related parties of the entity and their associates**	**Current quarter $A'000**
6.1	Aggregate amount of payments to related parties and their associates included in item 1	129
6.2	Aggregate amount of payments to related parties and their associates included in item 2	-

Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.

Payment to related parties as disclosed in item 6.1 as follows:

- $40,572 payments for non-executive director fees for the period;
- $88,036 payments to executive directors for the period, including superannuation paid during the quarter.

7.	**Financing facilities** *Note: the term "facility' includes all forms of financing arrangements available to the entity.* *Add notes as necessary for an understanding of the sources of finance available to the entity.*	**Total facility amount at quarter end $A'000**	**Amount drawn at quarter end $A'000**
7.1	Loan facilities	-	-
7.2	Credit standby arrangements	-	-
7.3	Other (please specify)	-	-
7.4	**Total financing facilities**	-	-

7.5	**Unused financing facilities available at quarter end**	-

7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.

N/A

8.	**Estimated cash available for future operating activities**	**$A'000**
8.1	Net cash from / (used in) operating activities (item 1.9)	(3,005)
8.2	Cash and cash equivalents at quarter end (item 4.6)	19,375
8.3	Unused finance facilities available at quarter end (item 7.5)	-
8.4	Total available funding (item 8.2 + item 8.3)	19,375
8.5	**Estimated quarters of funding available (item 8.4 divided by item 8.1)**	6.45

Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.

8.6 If item 8.5 is less than 2 quarters, please provide answers to the following questions:

8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?

Answer:
N/A

8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?

Answer:
N/A

8.6.3 Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?

Answer:
N/A

Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.

Compliance statement

1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.

2 This statement gives a true and fair view of the matters disclosed.

Date: 30 April 2026

Authorised by: The Board of Racura Oncology Limited
(Name of body or officer authorising release – see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.

2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.

3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.

4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [*name of board committee – eg Audit and Risk Committee*]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".

5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.